Timber pharmaceuticals announces publication of results from phase 2b control study of fda-designated breakthrough therapy tmb-001 in the journal of the american academy of dermatology

- previously reported study demonstrated clinically meaningful efficacy with a favorable safety profile for tmb-001 in moderate to severe congenital ichthyosis -

TMBR Ratings Summary

TMBR Quant Ranking